See Graham's ranking
5.0
Regeneron Pharmaceuticals, Inc. operates in the healthcare sector, within the biotechnology subsector, and was founded by Leonard Schleifer and George Yancopoulos. The initial motivation was tied to the development of therapies based on molecular biology to address complex diseases not resolved by conventional treatments.
There was no direct government involvement in its creation; the founders established the company as an independent research laboratory focused on biotechnological innovation and the application of genetic engineering to drug development.
Its main products and services include biological therapies and pharmaceuticals targeting areas such as immunology, ophthalmology, oncology, metabolic disorders, inflammatory diseases, and infectious diseases. The portfolio includes monoclonal antibodies, proprietary antibody-development technologies, and genetic discovery platforms.
The company operates in a global market, with product distribution in the United States, Canada, Europe, the Middle East, Asia, and Latin America, in addition to international partnerships for research, development, and commercialization activities.
Market factors influencing its operations include regulatory approval cycles, competition with other pharmaceutical and biotechnology companies, drug-pricing policies, advances in biological therapies, and increasing investment in research and development focused on next-generation antibody technologies.
Its operational structure and scale include thousands of employees distributed across research units, manufacturing centers, clinical laboratories, and corporate facilities. Infrastructure encompasses bioprocessing operations, clinical-development activities, and distribution networks serving international markets.
The operating model combines advanced research, biotechnological manufacturing, and strategic partnerships with other organizations in the pharmaceutical industry. Headquarters are located in Tarrytown, New York, with additional research and manufacturing units in Rensselaer, as well as subsidiaries dedicated to commercial and scientific operations in various countries.
Shares are traded on the Nasdaq under the ticker REGN.
History and Foundation
Founded in 1988 in Tarrytown, New York, Regeneron Pharmaceuticals was established with the objective of applying genetic engineering to the development of innovative therapies, with an early focus on foundational scientific research.
The initial years were marked by the establishment of laboratories, formation of multidisciplinary teams, and development of early research programs in neuroscience and cellular receptors, while facing the challenge of building competitiveness in the emerging biotechnology sector.
Expansion occurred through diversification into additional therapeutic areas, including immunology and ophthalmic diseases, and through the creation of proprietary antibody platforms that accelerated new drug discoveries and increased the commercial portfolio.
Key historical milestones include the launch of its first therapies approved by U.S. regulatory authorities, the completion of its initial public offering (IPO) in 1991 on the Nasdaq, and strategic partnerships established throughout the 2010s, including joint-development agreements with global companies.
Between 2020 and 2024, the company recorded significant advancements related to the expansion of therapeutic lines, investments in manufacturing capacity, growth of clinical programs, and development of next-generation antibody technologies. The period also included increased international operations and enhancements to scientific platforms, influencing market performance and strategic positioning.
Additional Information
The Company Regeneron Pharmaceuticals Inc. (United States), is listed on Nasdaq with a market cap of $ 78.61 Billions, having an equity of $ 30.96 Billions.
With a total of 9.123 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.
In the last 12 months the Company had a revenue of $ 14.25 Billions, which generated a profit in the amount of $ 4.58 Billions.
As for its main indicators, the Company has a P/E ratio of 17.17, a P/BV ratio of 2.54 and in the last 12 months the dividend yield of REGN was at 0.35%.
The Company is traded internationally through the ticker REGN.
